High-Yield P2X3 Inhibitor Synthesis for Industrial Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current clinical treatments for chronic refractory cough, such as gabapentin and morphine, are not suitable for long-term use due to adverse side effects, and there is a need for more effective P2X3 antagonists for treating chronic cough and urinary storage disorders.
Innovation Solution
A method for synthesizing 2-fluoro-5-(((2S,3R)-3-hydroxybutan-2-yl)oxy)-3-(5-methylthiazol-2-yl)-N-((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide, involving a series of condensation, hydrolysis, substitution, and coupling reactions, to facilitate high-yield industrial production of P2X3 inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing clinical treatments (gabapentin, morphine) are used for chronic cough, then cough symptoms can be alleviated, but adverse side effects occur and long-term use is not suitable
Solution Approach 1:
The patent develops novel P2X3 receptor antagonists with optimized molecular structures (compounds of formula I and its enantiomers/diastereomers) that selectively target the P2X3 receptor subtype. By changing the chemical parameters and molecular architecture, the new compounds achieve effective cough suppression while minimizing adverse side effects associated with conventional treatments like gabapentin and morphine.
2Manufacturing precision
If a complex multi-step synthesis method is used for P2X3 inhibitors, then product purity can be achieved, but production efficiency and yield are reduced
Solution Approach 1:
The patent divides the synthesis into modular stages: (a) preparing compound 1I through hydrolysis of compound 1H, (b) condensing compound 1I with compound 1L to produce the final P2X3 inhibitor. This segmented approach with clearly defined intermediates enables quality control at each stage while maintaining overall production efficiency.
Solution Approach 2:
The patent performs preliminary preparation of compound 1I (the acid component) before the final condensation step with compound 1L (the amine component). This preliminary action allows for optimization of each sub-step independently, ensuring high purity of intermediates while streamlining the overall synthesis pathway for industrial production.
3Quantity of substance
If existing P2X3 antagonist synthesis methods are used, then some product can be obtained, but yield is low and is not suitable for industrial production
Solution Approach 1:
The patent employs continuous optimization of reaction conditions throughout the synthesis pathway, including controlled hydrolysis of compound 1H to compound 1I, followed by continuous monitoring and optimization of the condensation reaction with compound 1L. This continuous approach maximizes yield at each stage and ensures the process is scalable for industrial production.
Solution Approach 2:
The patent optimizes critical parameters including reaction temperature, solvent selection, catalyst loading, and stoichiometry ratios in both the hydrolysis and condensation steps. These parameter changes are specifically designed to maximize product yield while maintaining conditions suitable for industrial-scale manufacturing.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a high-yield synthesis of P2X3 inhibitors suitable for industrial production, addressing the need for effective and safe long-term treatment options for chronic cough and urinary disorders.
Implementation Method 1
subjecting compound 1I and compound 1L to a condensation reaction as shown below under the action of a condensing agent and a base in a solvent to give compound I-1
Implementation Method 2
subjecting compound 1I and compound 1L to a condensation reaction as shown below under the action of a condensing agent and a base in a solvent to give compound I-1
Data Source
AI summary
The present invention belongs to the field of drug synthesis. Specifically, disclosed is a method for preparing a P2X3 inhibitor, i.e., 2-fluoro-5-(((2S,3R)-3-hydroxybutan-2-yl)oxy)-3(5-methylthiazol-2-yl)-N-((R)-1-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)benzamide (I-1). The method comprises the following steps: using 3-bromo-2-fluoro-5-iodobenzoic acid as a starting material, substituting iodine with a hydroxyl group and subjecting a carboxyl group to methyl esterification to obtain a compound 1C; subjecting the compound 1C and B2(pin)2 to a coupling reaction to obtain 1D; subjecting the compound 1D and 2-bromo-5-methylthiazole to a coupling reaction to obtain 1E; substituting the compound 1E with 1F to then obtain a compound 1H; hydrolyzing 1H under the action of a base to obtain 1I, and subjecting the compound 1I and 1L to a condensation reaction to obtain a product 1-1. The synthesis route provided by the present invention makes it easy to control product quality, has a high yield and is suitable for industrial production.